IN2014CN00827A - - Google Patents
Info
- Publication number
- IN2014CN00827A IN2014CN00827A IN827CHN2014A IN2014CN00827A IN 2014CN00827 A IN2014CN00827 A IN 2014CN00827A IN 827CHN2014 A IN827CHN2014 A IN 827CHN2014A IN 2014CN00827 A IN2014CN00827 A IN 2014CN00827A
- Authority
- IN
- India
- Prior art keywords
- methods
- amorphization
- crystallinity
- converting
- typical
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- 238000005280 amorphization Methods 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161524033P | 2011-08-16 | 2011-08-16 | |
PCT/US2012/050221 WO2013025449A1 (en) | 2011-08-16 | 2012-08-10 | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN00827A true IN2014CN00827A (pt) | 2015-04-03 |
Family
ID=47715376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN827CHN2014 IN2014CN00827A (pt) | 2011-08-16 | 2012-08-10 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20140206717A1 (pt) |
EP (1) | EP2744481A4 (pt) |
JP (1) | JP2014521745A (pt) |
CN (1) | CN103732216A (pt) |
AU (1) | AU2012295397A1 (pt) |
CA (1) | CA2844827A1 (pt) |
IN (1) | IN2014CN00827A (pt) |
WO (1) | WO2013025449A1 (pt) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
PL2456424T3 (pl) | 2009-07-22 | 2013-12-31 | Gruenenthal Gmbh | Stabilizowana przed utlenianiem odporna na naruszenie postać dawkowania |
AU2011297901B2 (en) | 2010-09-02 | 2014-07-31 | Grunenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
PT2736495T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente à adulteração proporcionando libertação imediata de fármaco |
ES2648129T3 (es) | 2011-07-29 | 2017-12-28 | Grünenthal GmbH | Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
AR090695A1 (es) | 2012-04-18 | 2014-12-03 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2014184378A1 (en) * | 2013-05-16 | 2014-11-20 | Sandoz Ag | Tablet with increased drug load of odanacatib |
EP2808012A1 (en) | 2013-05-29 | 2014-12-03 | ratiopharm GmbH | Method for producing dosage form comprising odanacatib |
KR20160031526A (ko) | 2013-07-12 | 2016-03-22 | 그뤼넨탈 게엠베하 | 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형 |
AU2014356581C1 (en) * | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
JP2017515897A (ja) * | 2014-05-09 | 2017-06-15 | アッヴィ・インコーポレイテッド | 結晶形 |
AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
KR102359641B1 (ko) * | 2016-03-31 | 2022-02-08 | 가부시키가이샤 폴라 파마 | 비정질화제, 비정질화제를 포함하여 이루어지는 비정질의 조성물 및 그 사용 |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
PT3448435T (pt) * | 2016-04-29 | 2022-07-26 | Rousselot B V | Excipiente à base de proteínas para princípios ativos farmacêuticos |
CN105943536A (zh) * | 2016-05-06 | 2016-09-21 | 杭州容立医药科技有限公司 | 一种固体分散体的制备方法及其应用 |
CN113271978B (zh) * | 2018-11-07 | 2025-04-04 | 创新制药公司 | 包括基本上无定形的介孔碳酸镁的新型无定形活性药物成分 |
MX2021010692A (es) * | 2019-03-04 | 2021-10-01 | Japan Tobacco Inc | Dispersion solida amorfa de compuesto de pirazol-amida. |
CN112023124B (zh) * | 2019-06-03 | 2022-11-29 | 上海微创医疗器械(集团)有限公司 | 结晶型涂层及其制备方法和应用 |
CN112300086B (zh) * | 2019-08-02 | 2022-03-15 | 苏州恩华生物医药科技有限公司 | 氯氮平与富马酸喹硫平共无定型物及其制备方法 |
WO2021259560A1 (en) | 2020-06-25 | 2021-12-30 | Omya International Ag | Co-ground active(s) comprising product comprising surface-reacted calcium carbonate |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ293841B6 (cs) * | 1996-05-20 | 2004-08-18 | Janssenápharmaceuticaán@Áv | Částice s obsahem itrakonazolu |
AU749623B2 (en) * | 1998-03-26 | 2002-06-27 | Astellas Pharma Inc. | Sustained release preparations |
MXPA03011933A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados. |
TNSN03138A1 (en) * | 2001-06-22 | 2005-12-23 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AN AMORPHOUS MEDICINAL PRODUCT |
US20050048112A1 (en) * | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US20070014846A1 (en) * | 2003-10-10 | 2007-01-18 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising fenofibrate and atorvastatin |
WO2005082330A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same |
WO2006046623A1 (ja) * | 2004-10-25 | 2006-05-04 | Japan Tobacco Inc. | 溶解性及び安定性の改善された固形製剤及びその製造方法 |
US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
CN101380474B (zh) * | 2007-09-06 | 2012-07-25 | 北京大学 | 用于口服制剂的pH敏感性固体药物组合物及制备方法 |
EP2231138A1 (en) * | 2008-01-03 | 2010-09-29 | Wockhardt Research Centre | Oral pharmaceutical suspension comprising paracetamol and ibuprofen |
EP2291079B1 (en) * | 2008-05-14 | 2013-04-24 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
EP2135601A1 (en) * | 2008-06-20 | 2009-12-23 | Capsulution Nanoscience AG | Stabilization of amorphous drugs using sponge-like carrier matrices |
AR072899A1 (es) * | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
EP2238979A1 (en) * | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
-
2012
- 2012-08-10 US US14/238,874 patent/US20140206717A1/en not_active Abandoned
- 2012-08-10 CA CA2844827A patent/CA2844827A1/en not_active Abandoned
- 2012-08-10 AU AU2012295397A patent/AU2012295397A1/en not_active Abandoned
- 2012-08-10 CN CN201280039578.7A patent/CN103732216A/zh active Pending
- 2012-08-10 JP JP2014526085A patent/JP2014521745A/ja not_active Withdrawn
- 2012-08-10 EP EP12823625.4A patent/EP2744481A4/en not_active Withdrawn
- 2012-08-10 IN IN827CHN2014 patent/IN2014CN00827A/en unknown
- 2012-08-10 WO PCT/US2012/050221 patent/WO2013025449A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JP2014521745A (ja) | 2014-08-28 |
WO2013025449A1 (en) | 2013-02-21 |
EP2744481A4 (en) | 2015-07-01 |
EP2744481A1 (en) | 2014-06-25 |
CN103732216A (zh) | 2014-04-16 |
AU2012295397A1 (en) | 2014-02-20 |
CA2844827A1 (en) | 2013-02-21 |
US20140206717A1 (en) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN00827A (pt) | ||
MX338327B (es) | Inhibidores de cdk. | |
NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
IN2013CN09704A (pt) | ||
CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
MY167126A (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
PH12012502255A1 (en) | Piperidinyl-substituted lactams as gpr119 modulators | |
PH12013502542B1 (en) | Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant | |
MY163979A (en) | Non-nucleoside reverse transcriptase inhibitors | |
WO2012090043A8 (en) | Novel solid state forms of azilsartan medoxomil and preparation thereof | |
MX345780B (es) | Inhibidores triciclicos de girasa. | |
MX2013002422A (es) | Sales de lorcaserina con acidos opticamente activos. | |
IN2014CN03857A (pt) | ||
GB201213267D0 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
SG10201900541QA (en) | Derivatives of xanthone compounds | |
MX2015007940A (es) | Compuestos tricíclicos como inhibidores de cftr. | |
EP2611799A4 (en) | PHARMACEUTICAL COMPOSITIONS OF LINEZOLID | |
IN2014DN00123A (pt) | ||
MY163074A (en) | Formulations comprising methylthioninium chloride | |
TR201000689A1 (tr) | Sefprozil içeren katı dozaj formlar. | |
UA104102C2 (en) | α-CRYSTALLINE FORM OF CARBABENZPYRIDE | |
IN2012CH02984A (pt) |